#NephJC Transcript
Healthcare social media transcript of the #NephJC hashtag.
– ().
See #NephJC Influencers/Analytics.
| Profile | Tweet |
|---|---|
 | jesse macs @lasvegaskidney RT @edgarvlermamd: MT @arvindcanchi @ISNeducation ANCA Vasculitis: MT @arvindcanchi @ISNeducation ANCA Vasculitis: Factors increasing risk of relapse #Nephpearls #NephJC #WCN2017 🇲🇽 https://t.co/xOF06Lcmdu |
| jesse macs @lasvegaskidney RT @edgarvlermamd: Potential therapeutic targets in ANCA Vasculitis #Nephpearls #NephJC 👉🏼 https://t.co/CCru5MgPfu https://t.co/gdPYNXFu6H |
 | Dr. Miguel A. Cota:. @macotav RT @ISNeducation: @edgarvlermamd @arvindcanchi This might be of interest from @macotav https://t.co/cv6m1TCwmg #nephJC #Nephpearls |
 | Ana Maria Matias @AMCMA6 RT @GlomCon1: Tonigh #NephJC will discuss the study of C5a receptor inhibitor in ANCA-associated vasculitis. We look forward to a glombastic discussion! https://t.co/SKZJf7adSv |
| Ana Maria Matias @AMCMA6 RT @edgarvlermamd: Pathogenesis of ANCA Vasculitis #NephJC 👉🏼 https://t.co/l2DB0cOldd https://t.co/rBGFKFScHw |
| Ana Maria Matias @AMCMA6 RT @edgarvlermamd: MT @arvindcanchi @ISNeducation ANCA Vasculitis: MT @arvindcanchi @ISNeducation ANCA Vasculitis: Factors increasing risk of relapse #Nephpearls #NephJC #WCN2017 🇲🇽 https://t.co/xOF06Lcmdu |
 | manuel macia heras @mmacia25 RT @NephJC: Less than 60 minutes to tonight's #NephJC Not too late to read the article: https://t.co/XQIiqDrL5j Or summary: https://t.co/ebwCRF1adF |
| Ana Maria Matias @AMCMA6 RT @ISNeducation: @edgarvlermamd @arvindcanchi This might be of interest from @macotav https://t.co/cv6m1TCwmg #nephJC #Nephpearls |
| Ana Maria Matias @AMCMA6 RT @NephRodby: Anything that spares or avoids steroids has Holy Grail potential #NephJC |
| Ana Maria Matias @AMCMA6 RT @NephRodby: Even though we save a life every time we dialyze, nothing is like bringing someone back from the dead from vasculitis #NephJC |
 | Sanjeev Nair @Nair_Sanj @KidneyCathy I am sure 1 of them did given I am the father. Not very sure about his mother though. #nephjc in the morning didn't exactly endear me 2 her😂 |
 | Fede P.S. @Sensingcrackest RT @edgarvlermamd: @NephRodby Potential therapeutic targets in ANCA Vasculitis #Nephpearls #NephJC 👉🏼 https://t.co/CCru5MyqE4 https://t.co/mPOpKDaM2y |
 | Trinity Kidneys @THKC1 RT @edgarvlermamd: Pathogenetic model highlighting differences between PR3-ANCA vs MPO-ANCA Vasculitis #Nephpearls #NephJC 👉🏼 https://t.co/ERXMI3qFB8 https://t.co/3kSVh4n1nT |
 | Dr.Ling @wenxinv RT @edgarvlermamd: Pathogenesis of ANCA Vasculitis #NephJC 👉🏼 https://t.co/l2DB0cOldd https://t.co/rBGFKFScHw |
 | Ernesto LopezAlmaraz @kidney_doctor RT @edgarvlermamd: Flow diagram for treatment of ANCA Vasculitis ca. 2015 #Nephpearls #NephJC 👉🏼 https://t.co/ERXMI3qFB8 https://t.co/qmnoDphueD |
 | V. Ocampo D @vod_md RT @edgarvlermamd: Pathogenesis of ANCA Vasculitis #NephJC 👉🏼 https://t.co/l2DB0cOldd https://t.co/rBGFKFScHw |
 | UmaraniMK @umaranigubbi RT @JMGardnerMD: RT @BethBraunhut: RT @BethBraunhut: Gorgeous example of membranous nephropathy. Looks at those spikes! #pathology #pathArt #nephJC https://t.co/xAUlZfEUR4 |
 | Luis Raul López @luisraulmt RT @edgarvlermamd: Pathogenetic model highlighting differences between PR3-ANCA vs MPO-ANCA Vasculitis #Nephpearls #NephJC 👉🏼 https://t.co/ERXMI3qFB8 https://t.co/3kSVh4n1nT |
 | Anace Pastor ✨️ Renalis 🌷@Anace710 @anace710 RT @edgarvlermamd: Pathogenesis of ANCA Vasculitis #NephJC 👉🏼 https://t.co/l2DB0cOldd https://t.co/rBGFKFScHw |
| Anace Pastor ✨️ Renalis 🌷@Anace710 @anace710 RT @GlomCon1: Tonigh #NephJC will discuss the study of C5a receptor inhibitor in ANCA-associated vasculitis. We look forward to a glombastic discussion! https://t.co/SKZJf7adSv |
 | Swapnil Hiremath @hswapnil@bsky.social @hswapnil RT @DearbhlaKelly4: |
 | Ester Sifuentes @T_Tsita RT @edgarvlermamd: Pathogenetic model highlighting differences between PR3-ANCA vs MPO-ANCA Vasculitis #Nephpearls #NephJC 👉🏼 https://t.co/ERXMI3qFB8 https://t.co/3kSVh4n1nT |
| Sanjeev Nair @Nair_Sanj RT @ISNeducation: @edgarvlermamd @arvindcanchi This might be of interest from @macotav https://t.co/cv6m1TCwmg #nephJC #Nephpearls |
| Ester Sifuentes @T_Tsita RT @NephJC: Can a rheumatologist comment on the suitability of the Birmingham score for acute change? #nephJC #RheumJC |
| Ester Sifuentes @T_Tsita RT @edgarvlermamd: C-ANCA Chocolate chip cookie 🍪 P-ANCA Popcorn 🍿 Credits: @ph_nachman #Nephpearls #NephJC https://t.co/f9f5tp1Vgs |
 | Manan Doshi @manan_doshi RT @ISNeducation: @edgarvlermamd @arvindcanchi This might be of interest from @macotav https://t.co/cv6m1TCwmg #nephJC #Nephpearls |
 | Kevin J. Fowler Principal The Voice of the Patient @gratefull080504 @VasculitisIA @VasculitisUK @vascuk @VasculitisFound @UKvasculiti : Here is the #storify from last night's #nephJC chat #vasculitis https://t.co/GF6RFOiJOA |
 | Pediatric Critical Care Medicine @PedCritCareMed The August @PedCritCareMed is out today, with FREE Feature Articles on their way! https://t.co/tS4CbqgIHl #sepsis #nephJC #airway #PedsICU https://t.co/7fWpmVVw0x |
 | Sapna Kudchadkar, MD, PhD @SapnaKmd RT @PedCritCareMed: The August @PedCritCareMed is out today, with FREE Feature Articles on their way! https://t.co/tS4CbqgIHl #sepsis #nephJC #airway #PedsICU https://t.co/7fWpmVVw0x |
 | Alice Ackerman, MD, @CloseToHomeMD RT @PedCritCareMed: The August @PedCritCareMed is out today, with FREE Feature Articles on their way! https://t.co/tS4CbqgIHl #sepsis #nephJC #airway #PedsICU https://t.co/7fWpmVVw0x |
| Kevin J. Fowler Principal The Voice of the Patient @gratefull080504 Thanks @ASNKidney for sharing the information about the #AskASN chat on #Kidneyweek17 I'll be there #nephJC #KidneyDisease https://t.co/WQtIjcSR4K |
 | Susan K 🇺🇦☮️ @bp1458 RT @PedCritCareMed: The August @PedCritCareMed is out today, with FREE Feature Articles on their way! https://t.co/tS4CbqgIHl #sepsis #nephJC #airway #PedsICU https://t.co/7fWpmVVw0x |
 | Johns Hopkins Pediatric Critical Care Medicine @HopkinsPedsCCM RT @PedCritCareMed: The August @PedCritCareMed is out today, with FREE Feature Articles on their way! https://t.co/tS4CbqgIHl #sepsis #nephJC #airway #PedsICU https://t.co/7fWpmVVw0x |
 | The Johns Hopkins PICU Up! Program @PICU_Up RT @PedCritCareMed: The August @PedCritCareMed is out today, with FREE Feature Articles on their way! https://t.co/tS4CbqgIHl #sepsis #nephJC #airway #PedsICU https://t.co/7fWpmVVw0x |
 | Syed Shahrul Naz @drshahrul80 RT @edgarvlermamd: C-ANCA Chocolate chip cookie 🍪 P-ANCA Popcorn 🍿 Credits: @ph_nachman #Nephpearls #NephJC https://t.co/f9f5tp1Vgs |
| Syed Shahrul Naz @drshahrul80 RT @edgarvlermamd: Flow diagram for treatment of ANCA Vasculitis ca. 2015 #Nephpearls #NephJC 👉🏼 https://t.co/ERXMI3qFB8 https://t.co/qmnoDphueD |
| Syed Shahrul Naz @drshahrul80 RT @edgarvlermamd: Renal Vasculitis #Nephpearls #NephJC https://t.co/M8K8c5qPBo |
| Syed Shahrul Naz @drshahrul80 RT @edgarvlermamd: Potential therapeutic targets in ANCA Vasculitis #Nephpearls #NephJC 👉🏼 https://t.co/CCru5MgPfu https://t.co/gdPYNXFu6H |
| manuel macia heras @mmacia25 RT @edgarvlermamd: Pathogenetic model highlighting differences between PR3-ANCA vs MPO-ANCA Vasculitis #Nephpearls #NephJC 👉🏼 https://t.co/ERXMI3qFB8 https://t.co/3kSVh4n1nT |
| Syed Shahrul Naz @drshahrul80 RT @PedCritCareMed: The August @PedCritCareMed is out today, with FREE Feature Articles on their way! https://t.co/tS4CbqgIHl #sepsis #nephJC #airway #PedsICU https://t.co/7fWpmVVw0x |
| Ana Maria Matias @AMCMA6 RT @edgarvlermamd: Pathogenetic model highlighting differences between PR3-ANCA vs MPO-ANCA Vasculitis #Nephpearls #NephJC 👉🏼 https://t.co/ERXMI3qFB8 https://t.co/3kSVh4n1nT |
| Ana Maria Matias @AMCMA6 RT @edgarvlermamd: Flow diagram for treatment of ANCA Vasculitis ca. 2015 #Nephpearls #NephJC 👉🏼 https://t.co/ERXMI3qFB8 https://t.co/qmnoDphueD |
| Kevin J. Fowler Principal The Voice of the Patient @gratefull080504 #KidneyDisease #RareDisease #esrd #vasculitis https://t.co/6Heu7NVHbP |
 | Joel M. Topf, MD FACP @kidney_boy Beta #VisualAbstract for tonight's (and last night's) #NephJC Avacopan for ANCA Associated Vasculitis, a phase 2 trial https://t.co/cgfVSqqp4I |
 | Arvind Canchi (Conjeevaram)🇮🇳 @arvindcanchi RT @kidney_boy: Beta #VisualAbstract for tonight's (and last night's) #NephJC Avacopan for ANCA Associated Vasculitis, a phase 2 trial https://t.co/cgfVSqqp4I |
 | NBLU: Renal Leaders @NBLUniv Great example of a #visualabstract!What font is that on the top line? https://t.co/ikxb83GMsH |
 | Raj Mehta @raj_mehta RT @kidney_boy: Beta #VisualAbstract for tonight's (and last night's) #NephJC Avacopan for ANCA Associated Vasculitis, a phase 2 trial https://t.co/cgfVSqqp4I |
 | Sibel Gokcay Bek @sibgokcay RT @kidney_boy: Beta #VisualAbstract for tonight's (and last night's) #NephJC Avacopan for ANCA Associated Vasculitis, a phase 2 trial https://t.co/cgfVSqqp4I |
 | Fadel Alrowaie @fadelrowaie RT @edgarvlermamd: C-ANCA Chocolate chip cookie 🍪 P-ANCA Popcorn 🍿 Credits: @ph_nachman #Nephpearls #NephJC https://t.co/f9f5tp1Vgs |
 | Haneen Al.Maghrabi @Haneen_Maghrabi RT @edgarvlermamd: C-ANCA Chocolate chip cookie 🍪 P-ANCA Popcorn 🍿 Credits: @ph_nachman #Nephpearls #NephJC https://t.co/f9f5tp1Vgs |
| Fadel Alrowaie @fadelrowaie RT @edgarvlermamd: Flow diagram for treatment of ANCA Vasculitis ca. 2015 #Nephpearls #NephJC 👉🏼 https://t.co/ERXMI3qFB8 https://t.co/qmnoDphueD |
| Fadel Alrowaie @fadelrowaie RT @edgarvlermamd: Renal Vasculitis #Nephpearls #NephJC https://t.co/M8K8c5qPBo |
 | Amer Mansour @am_altamimi RT @edgarvlermamd: Flow diagram for treatment of ANCA Vasculitis ca. 2015 #Nephpearls #NephJC 👉🏼 https://t.co/ERXMI3qFB8 https://t.co/qmnoDphueD |
 | Andrew M. Ibrahim MD, MSc (He/Him) @AndrewMIbrahim RT @kidney_boy: Beta #VisualAbstract for tonight's (and last night's) #NephJC Avacopan for ANCA Associated Vasculitis, a phase 2 trial https://t.co/cgfVSqqp4I |
 | UVA PICU @UVA_PICU RT @PedCritCareMed: The August @PedCritCareMed is out today, with FREE Feature Articles on their way! https://t.co/tS4CbqgIHl #sepsis #nephJC #airway #PedsICU https://t.co/7fWpmVVw0x |
 | Mana @manasigh RT @edgarvlermamd: Potential therapeutic targets in ANCA Vasculitis #Nephpearls #NephJC 👉🏼 https://t.co/CCru5MgPfu https://t.co/gdPYNXFu6H |
 | Brian Walsh PhD RRT @BrianKWalsh RT @PedCritCareMed: The August @PedCritCareMed is out today, with FREE Feature Articles on their way! https://t.co/tS4CbqgIHl #sepsis #nephJC #airway #PedsICU https://t.co/7fWpmVVw0x |
 | Rob Peel🏳️🌈💙🇬🇧🏴 @rabpeel On holiday , a shame because @NHSHRenal is part of a trial with it https://t.co/95eWwAjSO1 |
 | Mo Alzubaidi @NephrosisMo RT @kidney_boy: Beta #VisualAbstract for tonight's (and last night's) #NephJC Avacopan for ANCA Associated Vasculitis, a phase 2 trial https://t.co/cgfVSqqp4I |
| Kevin J. Fowler Principal The Voice of the Patient @gratefull080504 @KidneyPatients @RSNhope @PKDFoundation @KidneyResInst @kidneystories @GKH_org Hope you can join the conversation! #askasn #NephJC https://t.co/vp0A3rfXUa |
 | Nephrology Journal Club @NephJC T-90 minutes to #NephJC on Avacopan as a steroid alternative in ANCA vasculitis! All welcome! |
| Ana Maria Matias @AMCMA6 RT @manirath: @NephJC Ritux has come in big way. Now the first line of tx #NephJC |
 | Jim Myers @kidneystories RT @gratefull080504: @KidneyPatients @RSNhope @PKDFoundation @KidneyResInst @kidneystories @GKH_org Hope you can join the conversation! #askasn #NephJC https://t.co/vp0A3rfXUa |
| Nephrology Journal Club @NephJC Welcome to #NephJC tonight! I @DearbhlaKelly4 will be your host. Please introduce yourself and declare any COI. |
| Nephrology Journal Club @NephJC Tonight we are discussing Avacopan in ANCA-associated vasculitis. You can read the paper at https://t.co/XQIiqDrL5j #NephJC |
| Nephrology Journal Club @NephJC Or read or @toates_19 wonderful summary here https://t.co/ebwCRF1adF #NephJC |
| Nephrology Journal Club @NephJC We recommend using https://t.co/rFoH4MVMzu or TChat.io to follow the #nephjc chat. See a how to guide here: http//www.nephjc.com/how-to/ |
| Swapnil Hiremath @hswapnil@bsky.social @hswapnil Swapnil Hiremath from @OttawaHospital Lurking, but trying to make up for missing last night #NephJC https://t.co/cYKKd6X2Ru |
| Swapnil Hiremath @hswapnil@bsky.social @hswapnil RT @NephJC: Or read or @toates_19 wonderful summary here https://t.co/ebwCRF1adF #NephJC |
| Nephrology Journal Club @NephJC Let's kick off! T0: Steroids are the driving force for morbidity/mortality now in AAV. Who agrees? #NephJC |
 | soda_troubles,https://med-mastodon.com/@haysam @set_fortess RT @NephJC: Or read or @toates_19 wonderful summary here https://t.co/ebwCRF1adF #NephJC |
| Swapnil Hiremath @hswapnil@bsky.social @hswapnil @vascuk thanks for joining - and contributing to the @NephJC commentary! https://t.co/qyGAq881C8 @DearbhlaKelly4 #nephjc |
| Nephrology Journal Club @NephJC RT @hswapnil: @vascuk thanks for joining - and contributing to the @NephJC commentary! https://t.co/qyGAq881C8 @DearbhlaKelly4 #nephjc |
| Swapnil Hiremath @hswapnil@bsky.social @hswapnil T0: not sure. AAV pretty bad and nasty by itself (esp the renal cases seen by us). Steroids bad, AAV badder? #nephjc |
| Nephrology Journal Club @NephJC T0: the greatest threat to patients with AAV in their first year is adverse tx events #nephjc https://t.co/45gqAenklM |
| Swapnil Hiremath @hswapnil@bsky.social @hswapnil RT @DrMattGB: T0: |
| Nephrology Journal Club @NephJC RT @hswapnil: T0: T0: not sure. AAV pretty bad and nasty by itself (esp the renal cases seen by us). Steroids bad, AAV badder? #nephjc |
| Swapnil Hiremath @hswapnil@bsky.social @hswapnil RT @vascuk: |
| Nephrology Journal Club @NephJC T0: From EUVAS trials, 41% had hypertension, 38% osteoporosis, 28% diabetes mellitus and 25% had cataracts. #NephJC https://t.co/wNL6QYcxEJ |
| Nephrology Journal Club @NephJC RT @DrMattGB: T0: |
| Nephrology Journal Club @NephJC RT @vascuk: |
| Nephrology Journal Club @NephJC T0: Avacopan -small-molecule C5aR antagonist that blocks the effects of C5a, reducing neutrophil activation, accumulation & adhesion #NephJC |
 | Nathaniel Reisinger @nephrothaniel Nathaniel Reisinger. Nephrologist and clinical ultrasound fellow @PennKidney no pertinent COI #NephJC |
| Swapnil Hiremath @hswapnil@bsky.social @hswapnil RT @caioqualunque: T0: |
| Nephrology Journal Club @NephJC T0: Complement - the hipster bruncher of the immunology world at the moment! #NephJC |
| Swapnil Hiremath @hswapnil@bsky.social @hswapnil RT @NephJC: T0: T0: Avacopan -small-molecule C5aR antagonist that blocks the effects of C5a, reducing neutrophil activation, accumulation & adhesion #NephJC |
| Nephrology Journal Club @NephJC T1: Moving on to methods - Randomised, phase II, double-blind, placebo-controlled, trial running from 2011-2016 #NephJC |
| Nephrology Journal Club @NephJC T1: Interesting study design as exemplified in @kidney_boy visual abstract. Tx for just 12 wks #NephJC https://t.co/rLdiakG1gr |
| Swapnil Hiremath @hswapnil@bsky.social @hswapnil RT @NephJC: T1: T1: Interesting study design as exemplified in @kidney_boy visual abstract. Tx for just 12 wks #NephJC https://t.co/rLdiakG1gr |
| Nephrology Journal Club @NephJC RT @vascuk: |
| Nephrology Journal Club @NephJC @vascuk True but they seem to not be enough to prevent relapse? #NephJC |
| Joel M. Topf, MD FACP @kidney_boy @caioqualunque Help me out why is that both misleading and true? It was striking. I came this close to tweeting yesterday. #nephjc |
| Swapnil Hiremath @hswapnil@bsky.social @hswapnil @louise_oni Hey Louise, thanks for joining in! Welcome to #NephJC |
| Nephrology Journal Club @NephJC T1: What isn't clear from me from the methods is whether patients got methylprednisolone during induction with cyclophosphamide? #NephJC |
| Nephrology Journal Club @NephJC T1: Primary endpoint chosen was a decrease in Birmingham Vasculitis Activity Score of 50% or more – any issues with this? #NephJC |
| Joel M. Topf, MD FACP @kidney_boy Searched the whole document and the word methylprednisone wasn't used. #nephjc |
| Nephrology Journal Club @NephJC RT @caioqualunque: T0: |
| Swapnil Hiremath @hswapnil@bsky.social @hswapnil @kidney_boy @caioqualunque I am w/ Francesco. Citation 2: https://t.co/p8A7ImQ4qu true: infection > vascultitis misleading: would have likely died without Rx #NephJC https://t.co/hMTbiQnDED |
 | محذوف @milardport RT @NephJC: T-90 minutes to #NephJC on Avacopan as a steroid alternative in ANCA vasculitis! All welcome! |
| Swapnil Hiremath @hswapnil@bsky.social @hswapnil RT @NephJC: Methodology set up for one outcome - but results extrapolated to another. Thx @poyanmehr #nephjc https://t.co/oeSxkJWyJp |
| Swapnil Hiremath @hswapnil@bsky.social @hswapnil RT @vascuk: |
| Nephrology Journal Club @NephJC A single dose of MP can have lasting effects on immunity. It would be important to define if there was truly a steroid free arm #NephJC https://t.co/q6vh8Xka7g |
| Nephrology Journal Club @NephJC RT @hswapnil: @kidney_boy @caioqualunque I am w/ Francesco. Citation 2: @kidney_boy @caioqualunque I am w/ Francesco. Citation 2: https://t.co/p8A7ImQ4qu true: infection > vascultitis misleading: would have likely died without Rx #NephJC https://t.co/hMTbiQnDED |
| Nephrology Journal Club @NephJC RT @poyanmehr: @NephJC @kidney_boy that is where the confusion comes in. clearly not powered & designed for what we would like to see #nephjc |
| Swapnil Hiremath @hswapnil@bsky.social @hswapnil RT @alehkir: @caioqualunque #nephJC misleading b/c in spite of treatment-associated morbidity/mortality hard to argue: |
| Nephrology Journal Club @NephJC RT @DrMattGB: |
| Nephrology Journal Club @NephJC T1: If the study had used a pre-specified BVAS scores of 0 instead of relative change, would this have been more compelling? #NephJC |
| Nephrology Journal Club @NephJC T1: Analysis was intention to treat and based on non-inferiority #NephJC |
| Swapnil Hiremath @hswapnil@bsky.social @hswapnil @NephJC BVAS quite well accepted/validated (though I am w/ @DrMattGB on not being an expert on this; research tool > clinical use) #NephJC https://t.co/kcoBYO5eEk |
| Nephrology Journal Club @NephJC RT @caioqualunque: T1: |
| Nephrology Journal Club @NephJC RT @hswapnil: @NephJC BVAS quite well accepted/validated (though I am w/ @DrMattGB on not being an expert on this; research tool > clinical use) #NephJC https://t.co/kcoBYO5eEk |
| Swapnil Hiremath @hswapnil@bsky.social @hswapnil @NephJC Ah, 20% non-inferiority (same as RAVE ). Time for me to roll out the non-inferiority must read https://t.co/uEBHVQoHIB #nephjc https://t.co/8Ppq2l7e1S |
| Nephrology Journal Club @NephJC T2: Here is @toates_19 summary of efficacy findings. 'Tx response' seen in high proportion in all 3 grips #nephjc https://t.co/KaaTqs8Eqm |
| Swapnil Hiremath @hswapnil@bsky.social @hswapnil #NephJC https://t.co/KcvQTJ6AO2 |
| Nephrology Journal Club @NephJC RT @hswapnil: @NephJC Ah, 20% non-inferiority (same as RAVE ). Time for me to roll out the non-inferiority must read https://t.co/uEBHVQoHIB #nephjc https://t.co/8Ppq2l7e1S |
| Nephrology Journal Club @NephJC T2: Mostly new diagnoses though some relapses with equal split MPO and PR3 #NephJC |
| Swapnil Hiremath @hswapnil@bsky.social @hswapnil RT @NephJC: T2: T2: Here is @toates_19 summary of efficacy findings. 'Tx response' seen in high proportion in all 3 grips #nephjc https://t.co/KaaTqs8Eqm |
 | Vasculitis Stichting @Vasculitis_NL RT @caioqualunque: T0: |
| Nephrology Journal Club @NephJC T2: only key diff between groups was that placebo + pred group had worse renal disease at baseline but Ava renally protective? #NephJC |
| Nephrology Journal Club @NephJC Yes it's reassuring for PR3 patients albeit too short a trial to compare relapse rates #NephJC https://t.co/kz8j9CdNxE |
| Nephrology Journal Club @NephJC T2: Seems to be safe. Adverse events were similar across all groups, with 17% (4/23) control patients and 25% (11/44) ava patients #NephJC |
| Nephrology Journal Club @NephJC T2: Fewer side effects related to GC use were seen in patients on Ava (34% v 65%). Mainly fewer psych disorders and new DM. #NephJC |
 | Gates Colbert, MD @DoctorGates Dallas based Nephrologist. Lurking today and participating last night. #NephJC |
| Nephrology Journal Club @NephJC RT @caioqualunque: T0: |
| Nephrology Journal Club @NephJC Yes RITUXVAS was sponsored by La Roche I believe #NephJC https://t.co/4ilWn4B4gb |
| Nephrology Journal Club @NephJC RT @caioqualunque: T2: inclusion criteria: |
| Nephrology Journal Club @NephJC RT @alehkir: |
| Nephrology Journal Club @NephJC T2: Interestingly, more lymphopenia with avacopan compared with control/steroid group. Any explanations for this? #NephJC |
| Nephrology Journal Club @NephJC Really good point Fra! I didn't see that in study protocol? #nephJC https://t.co/BaDylLkCyH |
| Nephrology Journal Club @NephJC @Edwinwong00 will definitely know the answer to this! #NephJC |
| Nephrology Journal Club @NephJC RT @alehkir: @caioqualunque we're participating in the f/u study: |
| Nephrology Journal Club @NephJC T3: So is this a win for Avacopan to replace high dose steroids? Chemocentryx certainly seem to think so with phase 3 studies #NephJC |
| Nephrology Journal Club @NephJC T3: Definitely some valid statistical concerns as outlined by @toates_19 on their choice of primary outcome for a short study period #NephJC |
| Nephrology Journal Club @NephJC Don't think we know yet #NephJC https://t.co/ELYbgWxEtH |
| Swapnil Hiremath @hswapnil@bsky.social @hswapnil RT @alehkir: |
| Nephrology Journal Club @NephJC T3:It will be interesting to see longterm data given that previous concerns about steroid withdrawal were based on withdrawal < 1yr #NephJC |
| Nephrology Journal Club @NephJC https://t.co/qhM7JSPLev #NephJC |
| Nephrology Journal Club @NephJC RT @DrMattGB: |
| Nephrology Journal Club @NephJC RT @Errantnephron: |
| Swapnil Hiremath @hswapnil@bsky.social @hswapnil T3: not a perfect study. But rare/orphan dz, kudos to sponsor + researchers. Just happy new molecules being tested! #NephForward #nephjc |
| Nephrology Journal Club @NephJC RT @vascuk: |
| Swapnil Hiremath @hswapnil@bsky.social @hswapnil Yes! QFT MT @caioqualunque: We all want avacopan to win its race over steroids. #nephjc |
| Nephrology Journal Club @NephJC RT @alehkir: |
| Nephrology Journal Club @NephJC Time to wrap up I think! Thanks everyone for a really interesting discussion! #NephJC |
 | TOUNSI @TUNISIAMOUNTAIN Tunisian Journal of Medicine est sorti de presse! https://t.co/nGssMCYvCX Les unes d'aujourd'hui via @EMJRheum #arthritis #nephjc |
| Swapnil Hiremath @hswapnil@bsky.social @hswapnil RT @caioqualunque: |
 | Ed @Rx_Ed @NephJC Vaccination with avacopan likely not required because it's a receptor blocker. Eculizumab is a complement cleavage inhibitor. #NephJC |
| Joel M. Topf, MD FACP @kidney_boy Solid #NephJC w/ 633 Tweets 125 Participants btw 2 Chats. Thanks @KidneyCathy & @DearbhlaKelly4. 📊 https://t.co/NMvBBK8cWS via @symplur |
| Nephrology Journal Club @NephJC RT @Rx_Ed: @NephJC Vaccination with avacopan likely not required because it's a receptor blocker. Eculizumab is a complement cleavage inhibitor. #NephJC |
 | Krishna Penmatsa @krishnadoctor1 RT @caioqualunque: |
 | Poyan Mehr @poyanmehr RT @NephJC: Methodology set up for one outcome - but results extrapolated to another. Thx @poyanmehr #nephjc https://t.co/oeSxkJWyJp |
| soda_troubles,https://med-mastodon.com/@haysam @set_fortess RT @edgarvlermamd: MT @arvindcanchi @ISNeducation ANCA Vasculitis: MT @arvindcanchi @ISNeducation ANCA Vasculitis: Factors increasing risk of relapse #Nephpearls #NephJC #WCN2017 🇲🇽 https://t.co/xOF06Lcmdu |
| soda_troubles,https://med-mastodon.com/@haysam @set_fortess RT @edgarvlermamd: ANCA Vasculitis: ANCA Vasculitis: Predictors of treatment relapse/ resistance #Nephpearls #NephJC https://t.co/sBKk4ek8uS |
| soda_troubles,https://med-mastodon.com/@haysam @set_fortess RT @edgarvlermamd: Pathogenetic model highlighting differences between PR3-ANCA vs MPO-ANCA Vasculitis #Nephpearls #NephJC 👉🏼 https://t.co/ERXMI3qFB8 https://t.co/3kSVh4n1nT |
| soda_troubles,https://med-mastodon.com/@haysam @set_fortess RT @edgarvlermamd: Birmingham Vasculitis Activity Score (BVAS) #Nephpearls #NephJC https://t.co/bYPpe3xyt2 |
| soda_troubles,https://med-mastodon.com/@haysam @set_fortess RT @edgarvlermamd: Flow diagram for treatment of ANCA Vasculitis ca. 2015 #Nephpearls #NephJC 👉🏼 https://t.co/ERXMI3qFB8 https://t.co/qmnoDphueD |
| soda_troubles,https://med-mastodon.com/@haysam @set_fortess RT @edgarvlermamd: Renal Vasculitis #Nephpearls #NephJC https://t.co/M8K8c5qPBo |
| soda_troubles,https://med-mastodon.com/@haysam @set_fortess RT @edgarvlermamd: Potential therapeutic targets in ANCA Vasculitis #Nephpearls #NephJC 👉🏼 https://t.co/CCru5MgPfu https://t.co/gdPYNXFu6H |
| soda_troubles,https://med-mastodon.com/@haysam @set_fortess RT @edgarvlermamd: Pathogenesis of ANCA Vasculitis #NephJC 👉🏼 https://t.co/l2DB0cOldd https://t.co/rBGFKFScHw |
 | Alex Meraz @NephroGuy RT @NephJC: T1: T1: Interesting study design as exemplified in @kidney_boy visual abstract. Tx for just 12 wks #NephJC https://t.co/rLdiakG1gr |
 | Manish Rathi @manirath RT @hswapnil: T0: T0: not sure. AAV pretty bad and nasty by itself (esp the renal cases seen by us). Steroids bad, AAV badder? #nephjc |
 | Dr Mukesh Rulaniya @RulaniyaDr RT @caioqualunque: |
| Dr Mukesh Rulaniya @RulaniyaDr RT @caioqualunque: |
#NephJC content from Twitter.